GlassScriptPhysician profile
Shannon C Peterson
NPI 1699975235
$2,973.03
in general payments reported to CMS, 2019-2025
26 companies · $748 in 2025
The $748 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $188 · 2021: $277 · 2022: $572 · 2023: $512 · 2024: $387 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.93 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.32 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $429.98 | 2021-2025 | |
| Therapeuticsmd, INC. | $309.92 | 2019-2022 | |
| Sage Therapeutics, LLC | $202.42 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $194.99 | 2019-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $153.39 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $147.41 | 2019-2021 | |
| Novo Nordisk INC | $141.67 | 2024-2025 | Wegovy |
| Exeltis, USA INC. | $105.94 | 2019-2025 | Slynd |
| Myovant Sciences INC. | $100.69 | 2021-2022 | |
| Exact Sciences Corporation | $89.64 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $83.27 | 2023-2024 | |
| Agile Therapeutics, INC. | $70.04 | 2022-2023 | Twirla |
| Aspira Women'S Health INC | $65.48 | 2025 | Ova1 |
| Amag Pharmaceuticals, INC. | $64.91 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $58.04 | 2019-2020 | |
| Millicent US INC | $53.16 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Polynovo North America LLC | $47.24 | 2025 | Novosorb Btm |
| Bayer Healthcare Pharmaceuticals INC. | $46.71 | 2021-2025 | |
| Organon LLC | $44.49 | 2023-2025 | Nexplanon |
| Minerva Surgical, INC | $22.66 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.43 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $17.59 | 2024 | Gardasil 9, Gardasil |
| Coopersurgical, INC. | $17.24 | 2024 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $16.66 | 2021 | |
| Evofem Biosciences, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.